Skip to main content
. 2023 Jul 25;7(19):5898–5903. doi: 10.1182/bloodadvances.2023010539

Figure 2.

Figure 2.

Meta-analysis of combination versus mono-therapy and of BCMA-targeted versus non-BCMA targeted bispecifics. Comparison of (A) bispecific monotherapy vs (C) combination therapy trials and (B) BCMA-targeting bispecific antibodies vs (D) non-BCMA–targeting bispecific antibodies.